Lipoglycopeptide (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Lipoglycopeptide" in English language version.

refsWebsite

Global rank English rank

4^th place

2^nd place

5,225^th place

4,062^nd place

low place

11^th place

8^th place

399^th place

333^rd place

1^st place

447^th place

338^th place

68^th place

117^th place

clinicaltrials.gov

Kahne, Dan; Leimkuhler, Catherine; Lu, Wei; Walsh, Christopher (2005). "Glycopeptide and Lipoglycopeptide Antibiotics". Chemical Reviews. 105 (2): 425–448. doi:10.1021/cr030103a. PMID 15700951.
Zhanel, George G.; Calic, Divna; Schweizer, Frank; Zelenitsky, Sheryl; Adam, Heather; Lagacé-Wiens, Philippe R.S.; Rubinstein, Ethan; Gin, Alfred S.; et al. (2010-05-07). "New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin". Drugs. 70 (7): 859–886. doi:10.2165/11534440-000000000-00000. PMID 20426497. S2CID 207298905.
Kmeid J, Kanafani ZA (2015). "Oritavancin for the treatment of acute bacterial skin and skin structure infections: an evidence-based review". Core Evid. 10: 39–47. doi:10.2147/CE.S51284. PMC 4334198. PMID 25709561.
Corey GR, Loutit J, Moeck G, Wikler M, Dudley MN, O'Riordan W, et al. (2018). "Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies". Antimicrob Agents Chemother. 62 (4): e01919–17. doi:10.1128/AAC.01919-17. PMC 5914007. PMID 29358292.

Kahne, Dan; Leimkuhler, Catherine; Lu, Wei; Walsh, Christopher (2005). "Glycopeptide and Lipoglycopeptide Antibiotics". Chemical Reviews. 105 (2): 425–448. doi:10.1021/cr030103a. PMID 15700951.
Zhanel, George G.; Calic, Divna; Schweizer, Frank; Zelenitsky, Sheryl; Adam, Heather; Lagacé-Wiens, Philippe R.S.; Rubinstein, Ethan; Gin, Alfred S.; et al. (2010-05-07). "New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin". Drugs. 70 (7): 859–886. doi:10.2165/11534440-000000000-00000. PMID 20426497. S2CID 207298905.
Van Bambeke F. (August 2006). "Glycopeptides and glycodepsipeptides in clinical development: a comparative review of their antibacterial spectrum, pharmacokinetics and clinical efficacy". Curr Opin Investig Drugs. 7 (8): 740–9. PMID 16955686.
Kmeid J, Kanafani ZA (2015). "Oritavancin for the treatment of acute bacterial skin and skin structure infections: an evidence-based review". Core Evid. 10: 39–47. doi:10.2147/CE.S51284. PMC 4334198. PMID 25709561.
Corey GR, Loutit J, Moeck G, Wikler M, Dudley MN, O'Riordan W, et al. (2018). "Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies". Antimicrob Agents Chemother. 62 (4): e01919–17. doi:10.1128/AAC.01919-17. PMC 5914007. PMID 29358292.

Zhanel, George G.; Calic, Divna; Schweizer, Frank; Zelenitsky, Sheryl; Adam, Heather; Lagacé-Wiens, Philippe R.S.; Rubinstein, Ethan; Gin, Alfred S.; et al. (2010-05-07). "New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin". Drugs. 70 (7): 859–886. doi:10.2165/11534440-000000000-00000. PMID 20426497. S2CID 207298905.